This study is looking at using Ceftolozane/tazobactam for the treatment of hospital acquired pneumonia. This medication has been approved for use in abdominal infections, however, its use for pneumonia is investigational. It will be compared to meropenem.
Who may be Eligible
Eligible patients include: Patients are ventilated; proof of infiltrates on radiograph; meet clinical criteria as defined by the protocol; have normal maintenance labs as defined; not be treated with certain antibiotics prior to study; not be immunosuppressed; not have co-morbid conditions as defined by the protocol; contact the study team for details.